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REFLECTIONS OF THE PIONEERSThe Thrombolysis in Myocardial Infarction (TIMI) Study
Group experienceEugene Braunwald, MD, and Marc S. Sabatine, MD, MPH
The Thrombolysis in Myocardial Infarction (TIMI) study group, an academic research organization, was formed in
1984 with initial support from the National Heart, Lung, and Blood Institute. Its initial goal was to compare the effects
of the then-new thrombolytic agent, recombinant tissue plasminogen activator, with streptokinase. The TIMI study
group has remained active since then and has completed 50 multicenter clinical trials. The TIMI network now collab-
orates with more than 1000 separate sites in 45 countries on 5 continents. In addition to thrombolytic agents, TIMI has
studied antithrombotic, antiplatelet, anti-ischemic, lipid lowering, and anti-inflammatory drugs. TIMI has also estab-
lished robust biomarker and pharmacogenetics programs, and has devised a panel of risk assessment scores that are
widely used. TIMI is currently conducting 7 large trials worldwide on novel agents designed to reduce the morbidity
and mortality of a variety of cardiovascular disorders. (J Thorac Cardiovasc Surg 2012;144:762-70)THE ORIGINS OF TIMI
Although the idea of reperfusing infarcting myocardium in
the management of patients with acute myocardial infarc-
tion (MI) was developed in the early 1970s, it had its roots
much earlier. In 1935, Tennant and Wiggers1 demonstrated,
in open chest anesthetized dogs, that immediately after oc-
clusion of a major coronary artery the contraction of the
myocardium perfused by the occluded vessel became se-
verely impaired. Function recovered only if the obstruction
was relieved within 23 minutes. In 1941, Blumgart, Gilli-
gan, and Schlesinger2 also studied the consequences of
coronary artery occlusion and noted by both gross and mi-
croscopic examination that no infarction occurred in dogs in
which reperfusion was carried out up to 20 minutes after oc-
clusion and that with longer occlusions, the size of the in-
farct was proportional to the duration of the occlusion.
Although these early experiments demonstrated that myo-
cardial necrosis after coronary occlusion could be mini-
mized and even prevented by early reperfusion, neither of
these groups suggested that reperfusion was a potential ther-
apeutic intervention in patients with an evolving infarction.
In 1969, one of us (E.B.)3 proposed that the development
of cardiac pump failure could be reduced and that clinical
outcome improved by limiting the quantity of myocardium
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762 The Journal of Thoracic and Cardiovascular Surghypothesis was tested again in open chest anesthetized
dogs, and it was observed that the extent and severity of is-
chemic damage secondary to coronary occlusion could be
modified.4 From these experiments we concluded as
follows:
Of greatest interest, from the clinical point of view, is
the finding that the severity and extent of myocardial
ischemic injury resulting from coronary occlusion
could be radically altered not only by pretreatment
of the animal but also by an appropriate intervention
as late as three hours after the coronary occlusion.
This suggests that measures designed for reduction
of myocardial oxygen demands and improvement of
coronary perfusion, when effected promptly after
a patient has been brought to a hospital, might poten-
tially reduce the ultimate size of the infarction.*
We5 also observed that when coronary artery reperfusion
was carried out as late as 3 hours after occlusion, there was
less pathologic evidence of myocardial necrosis and im-
proved cardiac function than when the occlusion was
sustained.
When the fibrinolytic agent streptokinase was purified,
investigators began to determine whether this agent admin-
istered intravenously might be beneficial in the treatment of
patients with acute MI. A major step forward was taken in
1976 by Chazov, Mateeva, and Mazaev,6 who demon-
strated, using coronary arteriography, that the intracoronary
infusion of streptokinase lysed coronary thrombi and re-
stored myocardial reperfusion. Subsequently, we7 demon-
strated, using intracoronary thallium-201 myocardial
perfusion scanning, that myocardial tissue actually was
salvaged by the timely administration of intracoronary
streptokinase.*FromMaroko PR, Kjekshus JK, Sobel BE,Watanabe T, Covell JW, Ross J Jr, Braun-
wald E. Factors influencing infarct size following experimental coronary artery oc-
clusion. Circulation. 1971;43:67-82. Published with the permission of the
American Heart Association.
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ACS ¼ acute coronary syndrome
MI ¼ myocardial infarction
NSTEMI ¼ non–ST-elevation myocardial
infarction
PCI ¼ percutaneous coronary intervention
STEMI ¼ ST-elevation myocardial
infarction
TMPG ¼ TIMI Myocardial Perfusion
Grade
tPA ¼ tissue plasminogen activatorBy the middle 1980s, it was appreciated that for fibrino-
lytic therapy to be of practical benefit, the drug had to be ad-
ministered intravenously rather than by the intracoronary
route. Relatively few hospitals around the world had cathe-
terization laboratories, and even in those with such facilities
it often took hours to assemble the catheterization team,
take the patient to the laboratory, and infuse the lytic agent
directly into the occluded coronary artery. Also, a more
powerful and fibrin-specific lytic agent, produced by re-
combinant techniques, tissue plasminogen activator (tPA),
had been developed. In 1984, the US National Heart,
Lung, and Blood Institute established the Thrombolysis in
Myocardial Infarction (TIMI) Trial Study Group, a confed-
eration of experienced investigators and well-staffed and
equipped coronary care units. One of the authors (E.B.)
was asked to chair this group and did so until 2011, when
the other (M.S.S.) assumed this role. TIMI has been privi-
leged to have a number of talented senior investigators, in-
cluding Drs Elliott M. Antman, Christopher P. Cannon, C.
Michael Gibson, Robert P. Giugliano, David A. Morrow,
Deepak L. Bhatt.
Since its inception, the principal goal of the TIMI Study
Group has been to conduct high-quality clinical trials that en-
hance the care of patients with cardiovascular disease and its
risk factors. TIMI has been involved in 57 major studies,
which include a wide array of phase I to phase IV trials and
registries. These have ranged in size from less than 30 to
more than 26,000 subjects. Trials have been conducted in
45 countries and atmore than 1000 separate sites. The genesis
of a new clinical trial typically involves one of two pathways.
In some instances, TIMI identifies an unmet need or unan-
swered question in cardiovascular therapeutics that we be-
lieve can be addressed by studying an existing medication
for a new indication. In other cases, a pharmaceutical or bio-
technology company will approach us with a drug at preclin-
ical or early-stage clinical development and seek our counsel
as to the potential benefit of the drug and how it might best
be studied. Inasmuch as our time is our most preciousThe Journal of Thoracic and Cacommodity, we carefully vet any potential new trial, benefit-
ing from the collective experience and wisdom of both our
investigators and operational staff.
Although the initial TIMI trials focused on fibrinolytic
agents, we have also studied antithrombotic, antiplatelet,
anti-ischemic, lipid-lowering, and anti-inflammatory agents
as well as percutaneous coronary intervention (PCI). Al-
though the first trials involved patients with ST-elevation
myocardial infarction (STEMI), we have extended our
observations to other types of acute coronary syndrome
(ACS), as well as to patients with chronic coronary artery
disease, hyperlipidemia, and to the cardiovascular out-
comes in patients with diabetes mellitus. In addition, the
TIMI Study Group has used its growing database of clinical
findings, biomarkers, and genotypes to enhance the under-
standing of coronary artery disease. An equally important
goal has been to train the next generation of clinical inves-
tigators. Many of our postdoctoral fellows have assumed
important faculty positions at TIMI and elsewhere.
ST-ELEVATION MYOCARDIAL INFARCTION
(STEMI)
The effects of the then-new intravenously administered
tPA were compared with streptokinase on coronary and
clinical outcome in the TIMI group’s first trial.8 We ob-
served successful reperfusion of occluded coronary arteries
in 62% of patients who received tPA and 31% in those who
received streptokinase. Patients with a patent artery had
a lower mortality at 1 year than did those who did not,
leading to what we have termed the ‘‘early open artery
hypothesis’’ (Figure 1).
By the middle 1980s, percutaneous transluminal coro-
nary angioplasty had become widely used in the manage-
ment of severe angina pectoris in patients with stable
coronary artery disease, and it was suggested that it might
also be useful after fibrinolytic therapy in patients with
STEMI. Therefore, in the TIMI 2 trial we compared the
clinical outcome in patients who received tPA with either
a ‘‘late invasive strategy’’ consisting of coronary arteriog-
raphy 18 to 48 hours after the onset of symptoms,
followed by coronary revascularization if the anatomy
was appropriate, or a ‘‘conservative strategy,’’ in which
coronary arteriography and revascularization were carried
out only if recurrent ischemia occurred or a positive elec-
trocardiographic exercise stress test was present before
hospital discharge. We9 anticipated that the invasive
strategy would lead to improved clinical outcomes, but
we observed, in fact, that the incidence of death and recur-
rent MI was similar in the 2 groups. What we learned from
the TIMI 2 trial was that with the catheter-based revascu-
larization techniques of that era (which did not include its
performance on an emergency basis or stent implantation),
a routine invasive strategy was not necessary so long as
it was readily available for post-MI patients withrdiovascular Surgery c Volume 144, Number 4 763
FIGURE 1. The TIMI 1 trial enrolled 290 patients with acute myocardial infarction and randomized them to tissue plasminogen activator (tPA) or strep-
tokinase (SK).A, Patients treated with tPA (peach bars) had improved reperfusion and vessel patency at 90 minutes. (Data from the TIMI Study Group.8) B,
Regardless of treatment arm, a patent infarct-related artery at 90 minutes was associated with improved long-term survival. [FromDalen J, Gore JM, Braun-
wald E, Borer J, Goldberg RJ, Passamani ER, et al. Six- and twelve-month follow-up of the Phase I Thrombolysis inMyocardial Infarction (TIMI) trial. Am J
Cardiol. 1988;62:179-85.]
Reflections of the Pioneers Braunwald and Sabatinespontaneous or induced ischemia. Initially, the conserva-
tive approach after fibrinolytic therapy was widely adop-
ted around the world and in rural areas of North
America, whereas the invasive approach was used where
patients had rapid access to expert percutaneous translumi-
nal coronary angioplasty. At present, urgent primary PCI
is used whenever possible.
In theTIMI 2 trial, we also compared early intravenousme-
toprolol followed by oral administration of this beta-blocker
with oral beta-blocker begun on day 6. Early intravenous
beta-blockade was associated with statistically significant
reductions in reinfarction and in recurrent ischemia.10
Four later TIMI trials have examined the effects of ad-
junctive therapy in STEMI patients.
1. Early Retavase–Thrombolysis in Myocardial Infarction
(ER-TIMI 19): By 2000, the critical importance of min-
imizing the time from the onset of symptoms to the
administration of a fibrinolytic or initiating other reper-
fusion therapy was widely appreciated. WorldwideFIGURE2. Kaplan-Meier curves showing the superiority of enoxaparin (ENOX
(B) end points of the ExTRACT-TIMI 25 trial.12 RR, Relative risk; RRR, relati
764 The Journal of Thoracic and Cardiovascular Surgefforts were undertaken to develop strategies to reduce
this time interval. The TIMI 19 trial, led by Dr David
A. Morrow, showed that administration of a lytic agent
in the ambulance could reduce by one half the time inter-
val from ambulance arrival at the patient to starting
a fibrinolytic in the emergency department.11 Lytic ad-
ministration in the ambulance is now rarely applied in
North America because of thewidespread use of primary
PCI and the lack of trained personnel to administer fibri-
nolytics in the ambulance. However, this approach is
widely used in the remainder of the world. Also, radiote-
lemetry of the electrocardiogram from the ambulance to
the receiving hospital, as performed in the TIMI 19 trial,
shortens the ultimate ‘‘door to balloon time,’’ which has
become an important measure of the efficiency of hospi-
tal systems in managing patients with STEMI.
2. Enoxaparin and Thrombolysis Reperfusion for Acute
Myocardial Infarction Treatment–Thrombolysis in
Myocardial Infarction Study 25 (ExTRACT-TIMI 25):
Unfractionated heparin had been the antithrombotic) over unfractionated heparin (UFH) in the primary (A) andmain secondary
ve risk reduction. (From Antman et al.12)
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FIGURE 3. Death from cardiovascular causes in placebo and rivaroxaban
(2.5 mg twice daily) treated patients after acute coronary syndrome in AT-
LAS-2–TIMI 51.4 HR, Hazard ratio; BID, twice a day; NNT, number
needed to treat; mITT, modified intention to treat; ITT, intention to treat.
(From Mega et al.14)
FIGURE 4. TACTICS-TIMI 18 randomized 2220 patients with unstable
angina or non-STelevation myocardial infarction to an early invasive strat-
egy (INV) or conservative (CONS) strategy. MI, Myocardial infarction;
ACS, acute coronary syndrome; OR, odds ratio; CI, confidence interval.
(From Cannon et al.16)
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brinolytic therapy to prevent reocclusion after successful
lysis. This trial, led by Dr Elliott M. Antman, random-
ized 20,506 patients with STEMI receiving fibrinolytic
therapy to the low molecular weight heparin enoxaparin
for the entire period of hospitalization (median, 7 days)
or unfractionated heparin for 48 hours. At 30 days’
follow-up, enoxaparin significantly reduced the risk of
death or MI (the primary end point) by 17% and reduced
the risk of death, MI, or urgent revascularization by 19%
(Figure 2).12
3. Clopidogrel as Adjunctive Reperfusion Therapy–
Thrombolysis in Myocardial Infarction 28 (CLARITY-
TIMI 28): Early in the first decade of this century,
increasing attention was directed to the important role
of platelets in precipitating acute coronary events. This
trial, led by one of the present authors (M.S.S.) and Dr
Christopher P. Cannon, enrolled patients with STEMI re-
ceiving fibrinolytic therapy and aspirin and randomized
them to adjunctive clopidogrel or placebo. The addition
of clopidogrel significantly improved infarct-related ar-
tery patency and reduced the odds of adverse cardiovas-
cular events.13
4. Anti-Xa Therapy to Lower Cardiovascular Events in
Addition to Standard Therapy in Subjects With Acute
Coronary Syndrome–Thrombolysis in Myocardial In-
farction 51 (ATLAS-2–TIMI 51): The contemporary
treatment of STEMI includes urgent coronary arteriog-
raphy followed immediately by stenting if the anatomy
is suitable. Stent thrombosis is largely prevented by the
administration of aspirin and clopidogrel (or other
P2Y12 platelet receptor blockers). The ATLAS-2–TIMI
51 trial randomized 15,526 patients with an ACS, one
half of whom had STEMI (and other forms of ACS),The Journal of Thoracic and Cato placebo or 1 of 2 doses of the factor Xa inhibitor, ri-
varoxaban, begun an average of 4.7 days after the onset
of ACS (Figure 3). The very low dose (2.5 mg bid) re-
sulted in a 34% reduction in cardiovascular death (and
a 33% reduction in all-cause death) after treatment for
an average of 2 years.14 The 5-mg bid dose did not
have this salutary effect. These findings open the door
to adding a very low dose of an anticoagulant to dual
antiplatelet therapy in ACS.
NON–ST-ELEVATION ACS (NSTE-ACS)
Given the enormous and growing prevalence of NSTE-
ACS, that is, unstable angina and non-STEMI, the TIMI
Study Group has focused increasingly on this syndrome.
The addition of intravenous tPA to standard therapy in the
TIMI 3 trial did not improve outcome in this condition,15
an important negative trial inasmuch as many of these pa-
tients were receiving fibrinolytic therapy at the time. In
the Treat Angina With Aggrastat and Determine Cost of
Therapy With an Invasive or Conservative Strategy
(TACTICS-TIMI 18) trial, led by Dr Christopher P. Cannon,
an invasive strategy consisting of coronary arteriography
followed by revascularization if the anatomy was suitable,
was compared with a more conservative strategy in which
catheterization was carried out only if the patient experi-
enced recurrent ischemia or exhibited a positive stress
test.16 We observed a significant 22% reduction in the
odds of the primary end point of death, MI, or rehospitaliza-
tion in patients randomized to the invasive strategy at 6
months (Figure 4).
We also compared the low molecular weight heparin
enoxaparin with unfractionated heparin in 3910 patients
with NSTE-ACS in the TIMI 11 trial,17 which was led by
Dr Elliott M. Antman. As in the EXTRACT-TIMI 25 trial,
enoxaparin significantly reduced the risk of death, MI, orrdiovascular Surgery c Volume 144, Number 4 765
FIGURE 5. TRITON-TIMI 38 randomized 13,608 patients with acute
coronary syndrome undergoing percutaneous coronary intervention to pra-
sugrel or clopidogrel. HR, Hazard ratio; CV, cardiovascular; MI, myocar-
dial infarction; CABG, coronary artery bypass graft; NNT, number
needed to treat; NNH, number needed to harm; TIMI, Thrombolysis in
Myocardial Infarction. (From Wiviott et al.18)
Reflections of the Pioneers Braunwald and Sabatineurgent revascularization at 8 and 14 days. On the basis of
this and other trials, low molecular weight heparin is now
widely used around the world in patients with NSTE-ACS.
Inasmuch as platelets play an important role in the path-
ogenesis of ACS, the combination of 2 antiplatelet agents,
aspirin and the second-generation thienopyridine, clopidog-
rel, have become central in the treatment of this condition.
In the Trial to Assess Improvement in Therapeutic Out-
comes by Optimizing Platelet Inhibition With Prasugrel–
Thrombolysisin Myocardial Infarction 38 (TRITON-TIMI
38) trial, led by Dr Antman and Dr Stephen D. Wiviott,FIGURE 6. In TRITON-TIMI 38, subjects randomized to prasugrel had
a significant 52% reduction in the risk of stent thrombosis compared
with clopidogrel. This benefit was seen for both drug-eluting and bare-
metal stents. ARC, Academic Research Consortium; PCI, percutaneous
coronary intervention; HR, hazard ratio; NNT, number needed to treat.
(Modified from Wiviott et al.19)
766 The Journal of Thoracic and Cardiovascular Surga third-generation thienopyridine, prasugrel, more powerful
than clopidogrel, was compared with clopidogrel in 13,608
patients with ACS undergoing PCI.18 Prasugrel signifi-
cantly reduced the risk of the primary end point, that is,
death, MI, or stroke, by 19% (Figure 5) and stent thrombo-
sis by 52%19 (Figure 6). However, prasugrel significantly
increased the risk of major bleeding and, in patients with
prior stroke and transient ischemic attack, intracranial
bleeding. Patients with diabetes mellitus exhibited a partic-
ular benefit with prasugrel compared with clopidogrel with-
out a significant increase in major bleeding.20
We compared ranolazine, a piperazine novel anti-
ischemic drug, with placebo on 6560 patients in the Meta-
bolic Efficiency With Ranolazine for Less Ischemia in
Non–ST-Elevation Acute Coronary Syndromes–Thrombol-
ysis in Myocardial Infarction 36 (MERLIN-TIMI 36) trial,
led by Dr David A. Morrow.21 Although ranolazine did not
significantly reduce the risk of the composite end point of
cardiovascular death, MI, or recurrent ischemia, it signifi-
cantly reduced the risk of recurrent ischemia, supporting
its use as an anti-ischemic drug. Furthermore, ranolazine
had a favorable safety profile and significantly reduced
the incidence of ventricular tachycardia as recorded on
a Holter monitor by 37%22 and proved also to be a moder-
ately effective antidiabetic agent.23CHRONIC ATHEROSCLEROTIC DISEASE
Although aspirin is strongly indicated in patients after
MI, it is not clear whether platelet inhibition throughFIGURE 7. Comparison of intensive and standard lipid-lowering therapy
with statins after an acute coronary syndrome. After acute coronary
syndrome, intensive lipid-lowering therapy with a high-potency statin sig-
nificantly reduced the risk of adverse outcomes as compared with
moderate-potency statin therapy. MI, Myocardial infarction; RR, relative
risk. (From Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM,
Sacks FM, et al. Early and late benefits of high-dose atorvastatin in patients
with acute coronary syndromes. Results from the PROVE IT–TIMI 22 trial.
J Am Coll Cardiol. 2005;46:1405-10. Published with permission of the
American College of Cardiology Foundation.)
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FIGURE9. TRS, TIMI Risk Score for ST-elevationmyocardial infarction.
SBP, Systolic blood pressure; DM, diabetes mellitus; HTN, hypertension;
LBBB, left bundle branch block; STEMI, ST-elevation myocardial infarc-
tion; TIMI, Thrombolysis in Myocardial Infarction. (FromMarrow et al.28)
Braunwald and Sabatine Reflections of the Pioneersanother mechanism is beneficial. In the Thrombin Receptor
Antognist in Secondary Prevention of Atherosclerotic Is-
chemic Events–Thrombolysis in Myocardial Infarction 50
(TRA 2P–TIMI 50) trial, led by Dr David A. Morrow, we
compared vorapaxar, a potent protease-activated receptor-
1 platelet receptor inhibitor that blocks the platelet throm-
bin receptor, with placebo in 26,449 patients with stable
atherosclerosis. Overall, there was a significant reduction
in the primary end point of cardiovascular death, MI, or
stroke that appeared to be most robust in patients with prior
MI. In contrast, there was little or no benefit and an excess
of intracranial bleeding in stroke patients.24
CHOLESTEROL LOWERING
TIMI has been involved in studying the effects of lower-
ing cholesterol. The Pravastatin or Atorvastatin Evaluation
and Infection Therapy–Thrombolysis in Myocardial Infarc-
tion 22 (PROVE IT–TIMI 22) trial in patients after ACS, led
by Dr Christopher P. Cannon, studied the effects of what
was at the time (2001) considered to be extreme lowering
of low-density lipoprotein cholesterol.25 In this trial, 4162
post-ACS patients were randomized to intensive statin ther-
apy (atorvastatin 80 mg daily) or standard statin therapy
(pravastatin 40 mg daily). Intensive lipid lowering to
a mean of 62 mg/dL significantly reduced the risk of death,
MI, or urgent revascularization by 24% when compared
with standard therapy, which reduced low-density lipopro-
tein cholesterol to 95 mg/dL. This benefit of more intensive
lipid lowering with atorvastatin appeared within the first
month of starting therapy26 (Figure 7). This trial remains
one of our favorites for several reasons: the trial demon-
strated an unequivocal benefit; the findings were incorpo-
rated into practice guidelines and easily implemented by
clinicians; a wealth of secondary clinical, biomarker, and
genetic analyses have emanated from the trial database;FIGURE 8. The TIMI Risk Score for unstable angina (UA) and non–ST-
segment elevation myocardial infarction (NSTEMI) is a simple prognosti-
cation scheme that categorizes a patient’s risk of death and ischemic events.
CAD, Coronary artery disease; D/MI/UR, death, myocardial infarction,
urgent revascularization; ASA, aspirin; TIMI, Thrombolysis in Myocardial
Infarction. (From Antman et al.27)
The Journal of Thoracic and Caand, like any good experiment, the data have generated
new hypotheses to test in terms of further cholesterol reduc-
tion (see ‘‘Ongoing TIMI Trials’’) and the role of inflamma-
tion in cardiovascular disease.TIMI RISK SCORES
The TIMI Study Group has used its large database to es-
tablish clinical scores for risk stratification. The TIMI Risk
Score for NSTEMI-ACS is a simple 7-point scale that cat-
egorizes a patient’s risk of death and ischemic events and
provides a basis for therapeutic decision making27
(Figure 8). This score was derived in TIMI 11B and was
subsequently validated in several trials. The TIMI Risk
Score for STEMI consists of a 14-point scale based on
the history, physical examination, and presentation28
(Figure 9). The TIMI Risk Index is a simple index and is
based on a combination of age, heart rate, and systolic arte-
rial pressure at presentation, characteristics that are easily
assessed by nonphysicians in patients with STEMI. Every
5-point increase is associated with a 43% increase in
30-day mortality. The index was derived from the Intrave-
nous NPA for the Treatment of Infarcting Myocardium
Early–Thrombolysis in Myocardial Infarction 17 (InTIME
2–TIMI 17) trial and validated in TIMI 9 and 25 as well
as in the National Registry of Myocardial Infarction.29
The TIMI Coronary Flow Grade, established in the TIMI
1 trial, was designed to assess epicardial perfusion at angi-
ography.8 It is scored from 0 to 3, with TIMI Flow Grade
0 representing a total occlusion and TIMI FlowGrade 3 rep-
resenting normal epicardial perfusion. The TIMI Flow
Grade is a powerful predictor of clinical outcome
(Figure 10); its value has been confirmed in many trials
and it is now universally used. The number of cineangio-
graphic frames required for contrast medium to reach a stan-
dardized distal landmark after injection into a proximalrdiovascular Surgery c Volume 144, Number 4 767
FIGURE 10. TIMI FlowGrade is scored from 0 to 3. It is a powerful predictor of outcome. Here shown are the findings from the TIMI 1 trial. TIMI, Throm-
bolysis in Myocardial Infarction. [Data from Flyngenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E. Does arterial patency 90 minutes fol-
lowing thrombolytic therapy predict 42 day survival? J Am Coll Cardiol. 1991;17(Suppl A):275A.]
Reflections of the Pioneers Braunwald and Sabatinecoronary artery, termed the TIMI Frame Count, was estab-
lished by Dr C. Michael Gibson to enhance reproducibility
of the angiographic assessment of coronary blood flow. The
risk of adverse clinical outcomes rises proportionately with
an increased frame count.30
The TIMI Myocardial Perfusion Grade (TMPG), also de-
veloped by Dr Gibson, assesses microvascular perfusion of
the portion of the left ventricle in the area of distribution of
the culprit artery.31 It is scored from 0 to 3with TMPG 0 rep-
resenting no apparent tissue-level perfusion and TMPG 3
indicating normal perfusion. It too has been found to be
an independent predictor of clinical outcome.FIGURE 11. Efficacy outcomes (cardiovascular [CV] death, myocardial
infarction [MI], and stroke) among carriers of the CYP2C19 reduced
function allele in clopidogrel-treated patients in the TIMI 38 trial. CI,
Confidence interval. (From Mega et al.36)BIOMARKERS
The TIMI Group has had a strong interest in biomarkers
because of their ability to improve risk stratification. This
effort is led by Dr David A. Morrow. In the TIMI 3 trial
in patients with NSTEMI,32 patients with a serum troponin
greater than 9 ng/mL had a 7.5-fold higher risk of death than
patients with a troponin less than 0.4 ng/mL. In TACTICS-
TIMI 18, patients with an elevated troponin at baseline
appeared to derive a greater treatment benefit with an early
invasive strategy, as compared with patients without a tropo-
nin elevation.33
In Orbofiban in Patients with Unstable Coronary
Syndromes–Thrombolysis in Myocardial Infarction 16
(OPUS-TIMI 16), elevated levels of B-type natriuretic pep-
tide were associated with an increased risk of death, an
observation that was confirmed in the Aggrastat to Zocor–
TIMI 21 (A to Z–TIMI 21) trial.34
Three independent biomarkers (troponin, C-reactive pro-
tein, and B-type natriuretic peptide) were obtained on
admission in a multimarker strategy devised by Dr Marc
S. Sabatine. One point was assigned for each biomarker
that was abnormally elevated (troponin I> 0.1 mg/mL,768 The Journal of Thoracic and Cardiovascular SurgC-reactive protein>1.5 mg/dL, and B-type natriuretic pep-
tide>80 pg/mL). The relative risk rose progressively with
the number of elevated biomarkers.35PHARMACOGENETICS
Over the past several years, the TIMI Study Group has
delved into pharmacogenetics. Efforts led by M.S.S. and
Dr Jessica L. Mega demonstrated that approximately 30%
of individuals harbor a loss-of-function allele in the
CYP2C19 gene that results in lower levels of the active clo-
pidogrel metabolite, lesser degrees of platelet inhibition,
and, using patients from TRITON-TIMI 38 with an ACSery c October 2012
Braunwald and Sabatine Reflections of the Pioneersand planned PCI, approximately 50% higher risk of cardio-
vascular death, MI, or stroke, and more than a threefold in-
creased risk of stent thrombosis36 (Figure 11).
The subsequent Escalating Clopidogrel by Involving
a Genetic Strategy–Thrombolysis in Myocardial Infarction
56 (ELEVATE-TIMI 56) trial, led by Dr Mega, demon-
strated that it requires tripling the daily maintenance dose
of clopidogrel to achieve platelet inhibition equivalent to
that seen with the standard clopidogrel maintenance dose
in wild-type individuals.37ONGOING TIMI TRIALS
The TIMI Study Group is currently conducting 7 large-
scale multinational, multicenter trials. Improved Reduction
of Outcomes: Vytorin Efficacy International Trial–Throm-
bolysis in Myocardial Infarction 40 (IMPROVE IT–TIMI
40), led by Drs Cannon and Giugliano, and conducted in
collaboration with the Duke Clinical Research Institute, is
a randomized, double-blind trial designed to assess the pos-
sible benefit of treating more than 18,000 patients stabilized
after ACS to low-density lipoprotein cholesterol goals that
are even lower than those targeted in PROVE IT–TIMI
22, using a combination of simvastatin and ezetimibe.38
The ENGAGE-TIMI 48 trial, led by Drs Antman and
Giugliano, is comparing the novel factor Xa antagonist
edoxaban with warfarin in 20,500 patients with atrial fibril-
lation to look at the incidence of systemic embolism, stroke
and bleeding.39
The Stabilization of Plaques Using Darapladib–Throm-
bolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial,
led by Dr Cannon, is studying the effects of the lipoprotein-
PLA2 antagonist darapladib in 13,500 patients after ACS.40
The Saxagliptin Assessment of Vascular Outcomes Re-
corded in Patients With Diabetes Mellitus–Thrombolysis
in Myocardial Infarction 53 (SAVOR-TIMI 53) trial is
studying the effects of the DPP4 inhibitor saxagliptin on
cardiovascular outcomes in 16,500 patients with type 2
diabetes.41 The PEGASUS-TIMI 54 trial, led by M.S.S.,
is studying the effects of adding ticagrelor, a reversible
P2Y12 platelet receptor antagonist, to aspirin in patients 1
to 3 years after MI. The Randomized Evaluation of the
Effects of Anacetrapib Through Lipid-Modification–
Thrombolysis in Myocardial Infarction 55 (REVEAL
Hps-3–TIMI 55) trial, carried out in collaboration with
the Clinical Trial Service Unit at the University of Oxford,
is studying the cholesterol ester transport protein inhibitor
anacetrapib in 30,000 patients with chronic coronary artery
disease. This drug raises high-density lipoprotein choles-
terol and reduces low-density lipoprotein cholesterol. The
LDL-C Assessment With PCSK9 Monoclonal Antibody
Inhibition Combined With Statin Therapy–Thrombolysis
(LAPLACE-TIMI 57) trial, led by M.S.S., is studying
the effects of a potent new inhibitor of PCSK-9 onThe Journal of Thoracic and Calow-density lipoprotein cholesterol concentration in pa-
tients with hypercholesterolemia.42
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